Sang Taek Jung Ph.D.


                       
 

SANG TAEK JUNG

 

Department of Bio and Nano Chemistry

Kookmin University

Jeongneung-ro 77 Seongbuk-gu,

Seoul, Korea, 136-702

+82-10-3786-3149 (cell)

+82-2-910-5769 (office)

E-mail: sjung@kookmin.ac.kr

  EDUCATION                                                                                                                                                  


The University of Texas at Austin, (Austin, TX)

Ph.D. Chemical Engineering

Thesis: Engineering of Aglycosylated Antibody Fc for Effector Functions

 

Aug. 2004

Aug. 2009

Seoul National University, (Seoul, Korea)

M.S. Chemical Technology (Renamed Chemical and Biological Engineering)

Thesis: Production and Purification of Recombinant Human Erythropoietin in Escherichia coli and Chemical Modification with Monomethoxy Polyethylene Glycol

 

Mar.1997

– Feb. 1999

Seoul National University, (Seoul, Korea)

B.S. Chemical Technology (Renamed Chemical and Biological Engineering)

Thesis: ”Wear Properties of Polymer (Ultra-High Molecular Weight Polyethylene) for Artificial Bone”  

Magna cum laude (Class Rank: Ranked No. 2 from the Top in the Department)

 

 

Mar. 1993

– Feb. 1997

  RESEARCH EXPERIENCE                                                                                                                        

Assistant/Associate Professor

Department of Bio and Nano Chemistry, Kookmin University

Antibody Engineering, Protein Engineering, and Applied Immunology

 

Research Associate, Staff Scientist

Department of Chemical Engineering, The University of Texas at Austin

Advisor: Prof. George Georgiou

Applied Immunology

l  Antibody discovery via proteomic tools and bioinformatic analysis

l  Recruitment of endogenous antibodies for cancer immunotherapy

l  Engineering antibody for enhanced potency and stability

 

Seoul, Korea

Sep. 2012

– Present

 

 

Austin, TX

May 2011

– Aug. 2012

Post-Doctoral Fellow

Division of Chemistry and Chemical Engineering, California Institute of Technology

Advisor: Prof. Frances H. Arnold

Evolutionary Design of Biological Systems

l  Directed evolution of cytochrome P450 heme domain for ligand specific functional MRI contrast agents

l  Enzyme evolution for non-natural heme incorporated proteins

l  Directed evolution of cytochrome P450 BM3 for chemicals and biofuels

 

Pasadena, CA

Jun. 2010

– May 2011

Post-Doctoral Fellow

Department of Chemical Engineering, The University of Texas at Austin

Advisor: Prof. George Georgiou

Antibody Engineering

l  Engineering antibodies for selective binding to activating low affinity Fc receptors and enhanced therapeutic effector functions

l  Designing and screening of antibodies for improved HIV neutralization

 

Austin, TX Aug. 2009

– May 2010

 

Graduate Research Fellow (Research Assistant and Teaching Assistant)

Department of Chemical Engineering, The University of Texas at Austin

Advisor: Prof. George Georgiou

Antibody Engineering, High Throughput Screening, and Bacteria Physiology

l  Engineering of aglycosylated antibody Fc for unique effector functions

l  Development of a high throughput antibody screening system for insoluble antigens

l  Development of covalently anchored full length IgG display system

l  Bacterial production and characterization of human Fc receptors

l  Expression and purification of soluble Fab

Austin, TX Aug. 2004

– Aug. 2009

 

 

 

 

 

 

 

Research Scientist

Samyang Genex Biotech Research Institute

Development of Protein Therapeutics

l  Development of fermentation and purification process for human G-CSF from E. coli

l  Genetic optimization for high-level expression of G-CSF in E. coli

l  Cloning, production, and characterization of lysyl oxidase family proteins for anti-cancer drugs

 

 

Daejeon, Korea

May 2001

– Mar. 2004

Researcher

Green Cross Corporation

Development of Vaccines and Diagnostics

Researcher in Rotavirus Vaccine Research Team

l  Scale-up (75L scale) and optimization of baculovirus-infected insect cell (Sf9) culture for the production of rotavirus like particle (VLP) vaccine

l  Development of purification process for rotavirus like particle vaccine

l  Development of rotavirus detection kit (Rotatek™)

 

Yongin, Korea

Dec. 1998

– Apr. 2001

Graduate Research Fellow (Research and Teaching Assistant)

Seoul National University

Advisor: Prof. Cha Yong Choi

Protein Engineering

l  Production and purification of human erythropoietin in E. coli

l  Chemical modification of human erythropoietin using polyethylene glycol for the enhancement of half-life and serum stability

Seoul, Korea

Mar. 1997

– Feb. 1999

 

Undergraduate Research Fellow

Seoul National University

Advisor: Prof. Cha Yong Choi

Genetic Engineering

l  Cloning and expression of human erythropoietin in E. coli

 

 

Seoul, Korea

Aug. 1996

– Feb. 1997


TEACHING RELEVANT EXPERIENCE & ACTIVITIES                                                             

Assistant/Associate Professor

Kookmin University

l  Instructed undergraduate courses (Bionanopharmaceutics, Introduction to molecular biology, General chemistry, and Guide to life and career) and graduate courses (Protein engineering, Advanced biochemistry)

l  Advised and mentored one post-doctoral fellow, nine graduate students, and thirteen undergraduate students for antibody and protein engineering research projects.

 

Seoul, Korea

Sep. 2012

– Present

 

Graduate Student Research Supervisory Experience

The University of Texas at Austin

l  Mentored three graduate students and two post-doctoral fellows on their research projects – designed sets of experiments related to my researches, instructed the students for the theoretical and practical aspects of the experimental design, and met to discuss and interpret the results they acquired.

 

Austin, TX

May 2011

– Aug. 2012

 

Graduate Student/Post-doctoral Fellow Research Supervisory Experience

California Institute of Technology

l  Mentored one graduate student on her research projects

l  Helped one graduate student and one post-doctoral fellow to become familiar with the techniques used in their research, and assisted them to design experiments and interpret the results.

 

Pasadena, CA

May 2010 –May 2011

Teaching Assistant

The University of Texas at Austin

l  Biochemical Engineering – Conducted tutorials, held office hours, and marked assignments and exams.

 

Austin, TX

Aug. 2006

-May 2007

 

Undergraduate Student/Graduate Student/Post-doctoral Fellow/Visiting Scholar Research Supervisory Experience

The University of Texas at Austin

l  Trained seven researchers (one undergraduate student, three graduate students, one postdoctoral researcher, and two visiting scholars) for various experimental techniques (molecular biology, protein engineering, immunology, high throughput flow cytometry screening, and fermentation) and mentored on their research projects.

 

Austin, TX

Aug 2004

– May 2010

 

Teaching Assistant

Seoul National University

l  Biochemical Engineering - Conducted tutorials, held office hours, and marked exams.

l  Kinetics - Conducted tutorials, designed tests, prepared and marked exams.

l  Unit Operation - Conducted tutorials and marked exams.

l  Molecular Engineering Experiment – Delivered lectures on principles and procedures of experiments, supervised students in the laboratory, and marked their lab reports.

 

 

Seoul, Korea

Mar. 1997

 – Feb. 1998

 

INVITED TALKS                                                                                                                                      




  1. 2017 KSBEC (Korean Society of Industrial and Engineering Chemistry) Spring Meeting and International Symposium, Gwangju, Korea, 05/11/2013; For Prolonged Lifespan of Therapeutic Antibodies and Human.

  2. Samsung Bioepis, Suwon, Korea, 04/27/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  3. CJ Healthcare Corp., Seoul, Korea, 03/09/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  4. Samgyang Biopharm Corp., Seongnam, Korea, 02/28/2017; Evolutionary Approaches for Engineering Proteins.

  5. ABLBio, Seongnam, Korea, 02/24/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  6. Mogam Biotechnology Institute, Yongin, Korea, 02/23/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  7. Yuhan Research Institute, Yongin, Korea, 01/20/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  8. Celltrion Corp., Incheon, Korea, 01/06/2017; Engineering Antibodies for Improved Efficacy and Prolonged Serum Persistence.

  9. New Drug Development Platform Technology Boot Camp 2016, Seongnam, Korea, 12/21/2016; Technology for Maximizing Serum Half-Life of Biopharmaceutics.

  10. CJ Cheiljedang Corp., Suwon, Korea, 11/30/2016; Engineering Aglycosylated Full-Length IgG Antibodies for Next-Generation Immunotherapeutics.

  11. Korea Atomic Energy Research Institute, Daejeon, Korea, 11/25/2016; Engineering IgG Antibodies for Next-Generation Immunotherapeutics.

  12. College of Medicine, Yeonsei University, Seoul, Korea, 06/28/2016; Engineering antibodies for desired functions.

  13. 2016 Korean Society of Microbiology and Biotechnology Spring Meeting and International Symposium, Daejeon, Korea, 06/22/2016; Engineering antibodies for desired functions.

  14. 2016 Korean Society of Industrial and Engineering Chemistry Spring Meeting and International Symposium, Yeosu, Korea, 05/03/2016; Engineering antibodies for improved efficacy and prolonged serum half-life.

  15. Korea Food and Drug Administration, 04/20/2016; Engineering aglycosylated full-length IgG antibodies for next-generation immunotherapeutics.

  16. The Korean Society of Molecular Imaging, 02/26/2016; Engineering aglycosylated antibodies: no sugar? no problem.

  17. High1 New Drug Development Symposia, 01/14/2016; Highly evolvable antibody Fc domain.

  18. 21st Young Asian Biochemical Engineers Community (YABEC 2015), Chunchun, Korea, 10/15/2015; Bacterial display and high-throughput directed evolution of antibody therapeutics.

  19. PEGS Korea 2015, Seoul, Korea, 09/02/2015; Engineering aglycosylated full-length IgG antibodies for next-generation immunotherapeutics.

  20. GPCR Mini Symposium, Chunchun, Korea, 08/19/2015; High throughput directed evolution for next generation antibody pharmaceutics.

  21. KIST, Seoul, Korea, 07/22/2015; High throughput directed evolution for next-generation antibody pharmaceutics.

  22. The Antibody Society Korea Summer Workshop, Busan, Korea, 07/02/2015; Engineering aglycosylated full-length IgG antibodies for next generation immunotherapeutics.

  23. Biologics World 2015 Korea, Seoul, Korea, 06/10/2015; Fc engineered aglycosylated full-length IgG antibodies with novel effector functions.

  24. Molecular Science & Technology Center, Ajou University, Suwon, Korea, 01/28/2015; Reprograming protein structure and functions for novel pharmaceutics.

  25. Department of Chemical and Environmental Engineering, University of California at Riverside, Riverside, CA, 01/21/2015; Engineering Aglycosylated Full-Length IgG Antibodies for a New Class of Immunotherapeutics.

  26. Scripps Korea Antibody Institute, Chunchun, Korea, 12/02/2014; Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  27. Neopharm Corporation, Daejeon, Korea, 11/25/2014; Engineering Aglycosylated Full- Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  28. Department of Chemical Engineering, Kyung Hee Univerisity, Yongin, Korea, 11/06/2014; Antibody and Enzyme Engineering for Novel Biomedical and and Biocatalytic Applications.

  29. University of Ulsan College of Medicine, Seoul, Korea, 11/05/2014; Engineering Aglycosylated Full- Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  30. 2014 KSBB (Korean Society for Biotechnology and Bioengineering) Fall Meeting and International Symposium, Changwon, Korea, 10/06/2014; Directed Evolution of Cytochrome P450BM3 for Biocatalytic and Biomedical Applications.

  31. Korean Chemical Society Summer Workshop, Seoul, Korea, 08/25/2014; Evolutionary Approaches for Novel Protein Therapeutics and Diagnostics.

  32. Asia Pacific Protein Association, Jeju, Korea, 05/18/2014; Tailoring Aglycosylated Antibodies for a New Class of Next-Generation Immunotherapeutics.

  33. School of Chemical and Biological Engineering, Seoul National University, Seoul, Korea, 04/16/2014; Many Applications from One Enzyme: Engineering of Cytochrome P450BM3 Enzyme.

  34. 2014 KSBB (Korean Society for Biotechnology and Bioengineering) Spring Meeting and International Symposium, Gyeongju, Korea, 04/10/2014; Engineering Aglycosylated Antibodies for a New Class of Next-Generation Immunotherapeutics.

  35. Biological Engineering, Inha University, Incheon, Korea, 12/27/2014; Engineering Proteins for Next-Generation Pharmaceutics.

  36. Biological Engineering, Inha University, Incheon, Korea, 12/17/2014; Antibody Fc Engineering for Enhanced Potency and Prolonged Serum Half-Life.

  37. Daewoong Pharmaceutical Corporation, Yongin, Korea, 11/26/2013; Fc Engineering for Enhanced Potency and Prolonged Serum Half-Life.

  38. Scripps Korea Antibody Institute, Chuncheon, Korea, 11/26/2013; Fc Engineering for Enhanced Potency and Prolonged Serum Half-Life.

  39. Dasan conference, Hongcheon, Korea, 11/01/2013, Tailoring Aglycosylated Full-length IgG Antibodies for Enhanced Potency: No sugar? No problem.

  40. BioKorea, Ilsan, Korea, 09/13/2013; Tailoring Aglycosylated Full Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  41. Department of Biotechnology and Bioinformatics, Korea University, Sejong, Korea, 09/05/2013; Engineering Antibodies for Enhanced Potency.

  42. BioNanotechnology Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon, Korea, 07/18/2013; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  43. Department of Advanced Fermentation Fusion Science and Technology, Kookmin Univerisity, Seoul, Korea, 05/06/2013; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  44. 2013 KSBEC (Korean Society of Industrial and Engineering Chemistry) Spring Meeting and International Symposium, Jeju, Korea, 05/02/2013; Many Applications from One Enzyme: Engineering of Cytochrome P450BM3 Enzyme.

  45. 2013 KSBB (Korean Society for Biotechnology and Bioengineering) Spring Meeting and International Symposium, Kwangju, Korea, 04/12/2013; Tailoring Aglycosylated Full Length IgG Antibodies for Enhanced Potency.

  46. 2013 KSBB (Korean Society for Biotechnology and Bioengineering) Spring Meeting and International Symposium, Kwangju, Korea, 04/11/2013; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  47. KBio Osong Medical Innovation Foundation, Osong, Korea, 03/27/2013; Tailoring Aglycosylated Full Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  48. Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Korea, 03/19/2013; Tailoring Aglycosylated Full Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  49. Chong Kun Dang Research Institute, Yongin, Korea, 12/14/2012; Tailoring Aglycosylated Full Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  50. Department of Nano and Electronic Physics, Kookmin Univerisity, Seoul, Korea, 11/22/2012; Directed Evolution of Aglycosylated Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  51. 2012 The Korean Protein Society Annual Meeting and Symposium, 11/09/2012, Engineering Aglycosylated Full Length IgG Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  52. Celltrion, Inc, Incheon, Korea, 10/24/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  53. Molecular Science & Technology Center, Ajou University, Suwon, Korea, 05/21/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  54. Dong-A Pharmaceutical Corporation, Yongin, Korea, 04/20/2012; Directed Evolution of Aglycosylated Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  55. Department of Biotechnology, Yonsei Univerisity, Seoul, Korea, 04/19/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  56. KI for the BioCentury, KAIST (Korea Advance Institute of Science and Technology), Daejeon, Korea, 04/18/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  57. LG Life Sciences Corporation, Daejeon, Korea, 04/18/2012; Directed Evolution of Aglycosylated Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  58. Hanwha Chemical Corporation, Daejeon, Korea, 04/17/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  59. Department of Biological Engineering, Inha University, Incheon, Korea, 04/16/2012; Biomolecular, Cellular, and Evolutionary Approaches for Engineering Protein Therapeutics and Diagnostics.

  60. 2012 KSBB (Korean Society for Biotechnology and Bioengineering) Spring Meeting and International Symposium, Changwon, Korea, 04/13/2012; Directed Evolution of Aglycosylated Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  61. Isu Abxis Corporation, Seoul, Korea, 04/10/2012; Directed Evolution of Aglycosylated Antibodies: Bypassing Glycosylation, Novel Effector Functions, and Enhanced Potency.

  62. Department of Bioengineering, Stanford University, Stanford, CA, 02/18/2010; Engineering Aglycosylated Antibody Fc for Novel Effector Functions.

  63. Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 01/22/2010; Engineering Aglycosylated Antibody Fc for Novel Effector Functions.

  64. Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, 01/14/2010; Engineered Aglycosylated Antibody Exhibiting Unique Effector Functions.

  65. School of Chemical and Biological Engineering, Seoul National University, Seoul, Korea, 10/01/2009; Engineering Aglycosylated Antibody Fc for Effector Functions.

  66. Green Cross Corporation, Yongin, Korea, 09/29/2009; Antibody Engineering for Unique Effector Functions.

  67. Molecular Science & Technology Center, Ajou University, Suwon, Korea, 09/28/2009; Engineering Aglycosylated Antibody Fc for Effector Functions.

  68. Department of Chemical and Biomolecular Engineering, KAIST (Korea Advance Institute of Science and Technology), Daejeon, Korea, 09/24/2009; Engineering Aglycosylated Antibody Fc for Effector Functions.

  69. Department of Chemical Engineering, Pohang University of Science and Technology (POSTECH), Pohang, Korea, 09/18/2009; Engineering Aglycosylated Antibody Fc for Effector Functions.




PRESENTATIONS                                                                                                                                                      


1.    M. Jo, S. Ko, S. T. Jung*, (2016) “Engineering FcrRIIa for Improved IgG Fc Binding”,
      2016 KSIEC (Korean Society of Industrial and Engineering Chemistry) Fall Meeting and International Symposium.

2.    S. Ko, H. Yun, S. T. Jung*, (2016) “Engineered Flavin Mononucleotide-Based Fluorescent Protein.

3.    H. W. Yoon, S. T. Jung*, (2016) “Combination of Hot Spot Mutations of Antibody Fc for Enhanced Therapeutic Effector Functions”,
      2016 KSIEC (Korean Society of Industrial and Engineering Chemistry) Fall Meeting and International Symposium.

4.    H. I. Park, S. T. Jung*, (2016) “Engineering Aglycosylated Antibody Fc (mCH3) for Prolonged Serum Half-Life”,
      2016 KSIEC (Korean Society of Industrial and Engineering Chemistry) Fall Meeting and International Symposium.

5.    S. Lee, S. T. Jung*, (2016) “Engineering Auto-transporter-Mediated Bacterial Surface Display System”, 
      2016 Research Community For Functional antibody Screening System.

6.    S. Han, S. T. Jung*, (2016) “Biochemical insight into the ligand recognition mechanism of human endothelin receptor type A(ETA) for native peptide agonist, endothelin-1 (ET-1)”,
      2016 Research Community For Functional antibody Screening System.

7.    M. Ju, S. T. Jung*, (2016) “Human Synthetic, Semi-Synthetic, and Nae Immune Libraries for Efficient Isolation of Antigen Specific Antibodies”,
      2016 Research Community For Functional antibody Screening System.

8.    M. Ju, S. T. Jung*, (2015) “Structural Dynamics of Aglycosylated Fc Variants at Single Molecule Resolution”,
      IBC Antibody Engineering 2015 (San Diego, CA, USA).

9.    S. Ko, S. T. Jung*, (2015) “Engineering Fcγ Receptors for Enhanced IgG Binding Affinity”,
      2015 KORMB (The Korean Society for Microbiology and Biotechnology) Annual Meeting and International Symposium.

10.M. Jo, S. Ko, S. T. Jung*, (2015) “Aglycosylated IgG Antibody Fc Variants Engineered FcγRIIIa Engagement and NK Cell-Mediated Tumor Cell Killing”,
     2015 KSIECHEM (Korean Society of Industrial and Engineering Chemistry) Spring Meeting and International Symposium.

11.M. Ju, J. Na, C. Jeong, S. T. Jung*, (2015) “The Effect of FcγRI Binding Mutations on the Structural Flexibility of Upper CH2 Region of Aglycosylated Fc”,
     Peptalk 2015 (San Diego, CA, USA).

12.M. S. Ju, S. T. Jung*, (2014) “Construction and Validation of Single Domain Antibody Library”,
     2014 KSBEC (Korean Society of Industrial and Engineering Chemistry) Spring Meeting and International Symposium.

13.T. H. Kang, S. T. Jung, W. Kelton, G. Georgiou, (2014) “Aglycosylated Antibody Engineering for Novel Effector Functions”,
     Biomedical Engineering Society 2014 Annual Meeting.

14.M. Ju, S. H. Ko, M. Jo, S. T. Jung*, (2014) “Engineering Aglycosylated Antibodies for Next-Generation Immunotherapeutics”,
     The 4th Asia Pacific Protein Association (APPA) 2014 Conference.

15.W. Kelton, S. T. Jung, T. H. Kang, D. Ng, C. Sarkar, G. Georgiou, (2012) “Engineering Aglycosylated Fc Domains for Enhanced Effector Function”,
     Gordon Research Conferences, Antibody Biology and Engineering.

16.S. T. Jung, T. H. Kang, W. Kelton, G. Georgiou, (2011) “Covalently Anchored Full Length IgG Display System for Engineering Aglycosylation  
     Antibody Fc  domains”,      IBC’s 22nd Annual International Antibody Engineering Conference.

17.W. Kelton, S. T. Jung, T. H. Kang, Y. Wine, G. Georgiou, (2011) “Aglycosylated Antibody Fc Domains Engineered to Improve Selectivity for
     Activating FcγRIIa over FcγRIIb”,      IBC’s 22nd Annual International Antibody Engineering Conference.

18.Y. Wine, D. R. Boutz, J. J. Lavinder, A. E. Miklos, R. A. Hughes, K. H. Hoi, S. T. Jung, A. P. Horton, A. D. Ellington, E. M. Marcotte, G. Georgiou,
     (2011) ”Molecular Deconvolution of the Polyclonal Antibody Serum Response”, IBC’s 22nd Annual International Antibody Engineering Conference.

19.S. T. Jung, T. H. Kang, W. Kelton, S. Pai, G. Georgiou, (2011) “Reprogramming the Effector Functions of Herceptin for Increased Therapeutic Potency”,
     Annual CPRIT (Cancer Prevention and Research Institute of Texas) conference.

20.W. Kelton, S. T. Jung, T. H. Kang, Y. Wine, M. J. Borrok, G. Georgiou, (2011)
     “Aglycosylated Fc Variants Engineered for Improved Discrimination between the FcγRIIa and FcγRIIb”,   Keystone Symposia, Antibodies as Drugs.

21.S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, G. Georgiou, (2009)
     “Engineered, Bacterially Expressed, Aglycosylated Antibody Fc Variants Exhibiting Unique Effector Functions”, 
      IBC’s 20th Annual International Antibody Engineering Conference.

22.S. T. Jung, T. H. Kang, I. Sandlie, P. W. Tucker, G. Georgiou, (2008) “Engineering of Aglycosylated Fc for Selective Binding to Fcγ Receptors and
     Effector Functions”,   AIChE Annual Meeting.

23.S. T. Jung, G. Georgiou, (2007) “Engineering of Novel Aglycosylated Fc for Effector Functions”, IBC’s 18th Annual International Antibody Engineering Conference.

24.M. J. Seo, K. J. Jeong, S. T. Jung, B. L. Iverson, G. Georgiou (2005)
     “Engineering of Highly Soluble Fab Fragments in the Periplasm of Escherichia coli by Anchored Periplasmic Expression (APEx)”,
      International Biochemical Engineering XIV Conference.

25.J. Y. Park, S. T. Jung, S. H. Kim, H. Kim, and C. N. An, (1999) “Development of a Rotavirus Detection Kit for the Surveillance of Rotaviral Diarrheal Disease”,
       81st Annual Meeting of the Korean Society for Microbiology.

26.J. Y. Park, S. T. Jung, S. H. Kim, H. Kim, and C. N. An, (1999) “Detection of a Rotavirus Antigen from Diarrheal Fecal Samples of Infants”,
      31st Annual Meeting of the Korean Society of Virology.



AWARDS AND HONORS                                                                                                                        

l  Student Poster Scholarship Award, IBC Antibody Engineering Conference (2007)

l  University Pre-emptive Recruitment Fellowship, The University of Texas at Austin (2004-2006)

l  University Scholarship Award, Graduate School of Seoul National Univ. (1998-1999)

l  Magna Cum Laude Honors, Seoul National University (Feb. 1997)

l  Alumni Scholarship Award, Alumni Association of Seoul National University (1996-1997)

l  University Scholarship Award, Seoul National University (1994-1996)